H2 Receptor Antagonists — MCQs
What is the treatment of choice in duodenal ulcer without any complications of hemorrhage?
Which of the following is the most common side effect of Cimetidine?
Proton pump inhibitors are most effective when they are given:
What is the drug of choice for drug-induced peptic ulcer?
Identify the correct match, regarding the drug and its adverse effect.
The anticoagulant activity of warfarin can be reduced by all of the following except.
Which of the following is not a side effect of topical beta blockers?
Mechanism of action of teduglutide in short bowel syndrome:-
Which of the following is an H2 receptor antagonist used as an anti-ulcer drug?
Which of the following statement is correct regarding the given DRC? (AllMS Nov 2016)
H2 Receptor Antagonists Indian Medical PG Practice Questions and MCQs
Question 1: What is the treatment of choice in duodenal ulcer without any complications of hemorrhage?
- A. Highly selective vagotomy
- B. Trunkal vagotomy
- C. Proton pump inhibitors (Correct Answer)
- D. None of the options
Explanation: ***Proton pump inhibitors*** - **Proton pump inhibitors (PPIs)** are the first-line and most effective treatment for uncomplicated duodenal ulcers due to their potent and sustained acid suppression [1]. - They work by irreversibly inhibiting the **H+/K+-ATPase pump** in the stomach's parietal cells, reducing acid secretion and allowing the ulcer to heal [1]. *Highly selective vagotomy* - This is a surgical procedure that was historically used to reduce acid secretion by denervating the acid-producing parietal cells of the stomach, but it is **not the primary treatment** for uncomplicated ulcers today due to the availability of effective medical therapy [1]. - It carries surgical risks and is generally reserved for **refractory cases** or those with complications not amenable to endoscopic or medical management [1]. *Trunkal vagotomy* - **Trunkal vagotomy** involves cutting the main vagal trunks, which leads to significant side effects such as **gastric stasis** (delayed emptying) and diarrhea, often requiring a drainage procedure (e.g., pyloroplasty). - It was used in the past but is **rarely performed** for uncomplicated duodenal ulcers due to its associated morbidity and the effectiveness of modern medical treatments [1]. *None of the options* - This option is incorrect because **proton pump inhibitors** are indeed a highly effective and standard treatment for uncomplicated duodenal ulcers [1].
Question 2: Which of the following is the most common side effect of Cimetidine?
- A. Diarrhea
- B. Impotence
- C. CNS effects (confusion, dizziness) (Correct Answer)
- D. Gynaecomastia
Explanation: ***CNS effects (confusion, dizziness)*** - **Cimetidine** is a **H2-receptor antagonist** that can cross the **blood-brain barrier**, leading to **central nervous system (CNS) side effects**. - These effects, including **confusion, dizziness**, and **headache**, are more common in elderly patients or those with renal impairment due to reduced drug clearance. *Impotence* - While **cimetidine** can cause **endocrine effects** due to its anti-androgenic activity, **impotence** is a less common side effect compared to CNS disturbances. - It results from the drug's interference with **testosterone metabolism** and binding to **androgen receptors**. *Gynaecomastia* - **Gynaecomastia** is a known **endocrine side effect** of **cimetidine** due to its **anti-androgenic activity** and promotion of **prolactin release**. - However, CNS side effects are generally encountered more frequently in clinical practice. *Diarrhea* - **Gastrointestinal side effects** like **diarrhea** are possible with various medications, but they are not the most common or characteristic side effect of **cimetidine**. - Nausea and constipation are also reported, but generally less frequently than CNS effects.
Question 3: Proton pump inhibitors are most effective when they are given:
- A. After meals
- B. Shortly before meals (Correct Answer)
- C. Along with H2 blockers
- D. During prolonged fasting periods
Explanation: ***Shortly before meals*** - **Proton pump inhibitors (PPIs)** are most effective when administered 30-60 minutes before a meal because they need to be present when **parietal cells are actively secreting acid**. - PPIs are **prodrugs** that become activated in the acidic environment of the parietal cell secretory canaliculus and then irreversibly bind to the **H+/K+ ATPase pump**. - Taking them before a meal ensures that the drug is absorbed and reaches the parietal cells just as they are being stimulated to secrete acid in response to food, maximizing the number of pumps that can be inhibited. *After meals* - Taking PPIs after meals is less effective because a significant portion of the drug may have already been absorbed during a period of lower parietal cell activity. - This timing misses the optimal window when the maximum number of **proton pumps** are being inserted into the canalicular membrane in response to the meal stimulus. - Additionally, food can interfere with the absorption of some PPIs, further reducing effectiveness. *Along with H2 blockers* - While both PPIs and **H2 blockers** reduce gastric acid through different mechanisms, combining them does not provide significant additional benefit for most conditions. - H2 blockers reduce the basal stimulation of parietal cells, which means fewer pumps are actively secreting when the PPI is present, potentially reducing the number of pumps available for PPI binding. - Routine combination therapy is generally not recommended except in specific refractory cases. *During prolonged fasting periods* - During **fasting**, parietal cells are relatively inactive with minimal pump activity in the secretory canaliculus. - PPIs are most effective when they can bind to actively functioning **H+/K+ ATPase pumps**, which are minimal during fasting states. - This results in fewer pumps being irreversibly inhibited, leading to suboptimal acid suppression.
Question 4: What is the drug of choice for drug-induced peptic ulcer?
- A. Prostaglandin analogues
- B. H2-receptor antagonists
- C. Proton pump inhibitors (Correct Answer)
- D. Antacids
Explanation: ***Proton pump inhibitors*** - **PPIs** are the most effective agents for treating and preventing **NSAID-induced peptic ulcers** by profoundly suppressing gastric acid secretion. - They provide **rapid symptom relief** and promote ulcer healing by creating an environment conducive to mucosal repair. *Prostaglandin analogues* - **Misoprostol**, a prostaglandin E1 analogue, can prevent NSAID-induced ulcers, but its use is limited by **gastrointestinal side effects** such as diarrhea and abdominal cramping. - While they protect the gastric mucosa, their efficacy in healing established ulcers is generally **inferior to PPIs**. *H2-receptor antagonists* - **H2-blockers** are effective in reducing gastric acid, but they are **less potent** than PPIs and typically do not heal **gastric ulcers** as effectively, especially those induced by NSAIDs. - They are more commonly used for preventing **duodenal ulcers** and managing symptoms of GERD. *Antacids* - Antacids provide **immediate, temporary relief** of ulcer symptoms by neutralizing existing stomach acid. - They do not address the underlying pathology or promote **ulcer healing** and are therefore not considered the drug of choice for treatment.
Question 5: Identify the correct match, regarding the drug and its adverse effect.
- A. Aliskiren - hypokalemia
- B. Hydralazine - heart failure
- C. Atenolol - hemolytic anemia
- D. Verapamil - constipation (Correct Answer)
Explanation: ***Verapamil - Constipation*** - **Verapamil**, a **non-dihydropyridine calcium channel blocker**, frequently causes constipation due to its effect on smooth muscle in the gastrointestinal tract, leading to **decreased intestinal motility**. - This adverse effect is common and often dose-dependent, making it a significant consideration in patient management. *Aliskiren - hypokalemia* - **Aliskiren**, a **direct renin inhibitor**, can cause **hyperkalemia** by reducing angiotensin II levels, which normally stimulate aldosterone secretion. - It does not typically cause hypokalemia; rather, potassium-sparing effects are often observed. *Hydralazine - heart failure* - **Hydralazine** is a **vasodilator** used to treat hypertension and **heart failure** with reduced ejection fraction by reducing afterload. - It does not cause heart failure; instead, it is often prescribed to improve cardiac function in patients with heart failure. *Atenolol - hemolytic anemia* - **Atenolol** is a **beta-blocker** primarily used for hypertension, angina, and arrhythmias. - **Hemolytic anemia** is a rare adverse effect associated with certain drugs, but it is not a known or common side effect of atenolol.
Question 6: The anticoagulant activity of warfarin can be reduced by all of the following except.
- A. Aspirin (Correct Answer)
- B. Rifampin
- C. Vitamin K
- D. Carbamazepine
Explanation: ***Aspirin*** - **Aspirin** does NOT reduce warfarin's anticoagulant activity; instead, it increases the risk of bleeding through a synergistic effect. - Aspirin inhibits platelet aggregation via **cyclooxygenase-1 (COX-1)** inhibition, preventing thromboxane A2 formation, which is a different mechanism from warfarin's inhibition of vitamin K-dependent clotting factors. - When combined with warfarin, aspirin **potentiates** the overall antithrombotic effect and increases bleeding risk. *Carbamazepine* - **Carbamazepine** is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - By increasing warfarin metabolism, it **reduces** warfarin's plasma concentrations and decreases its anticoagulant effect. - Patients on this combination may require higher warfarin doses to maintain therapeutic INR. *Rifampin* - **Rifampin** is one of the most potent inducers of hepatic cytochrome P450 enzymes (CYP2C9, CYP3A4). - It significantly increases warfarin metabolism, leading to **reduced** plasma concentrations and diminished anticoagulant effect. - This interaction often necessitates substantial increases in warfarin dosage. *Vitamin K* - **Vitamin K** is the direct antagonist of warfarin's mechanism of action. - Warfarin inhibits vitamin K epoxide reductase, preventing the regeneration of active vitamin K needed for synthesis of clotting factors II, VII, IX, and X. - Administration of vitamin K **reverses** warfarin's anticoagulant effect by bypassing the inhibited enzyme and restoring clotting factor production.
Question 7: Which of the following is not a side effect of topical beta blockers?
- A. Heterochromia iridis (Correct Answer)
- B. Asthma
- C. Hypoglycemia
- D. Bradycardia
Explanation: ***Heterochromia iridis*** - **Heterochromia iridis** (different colored irises) is a well-known side effect of **prostaglandin analogs** (e.g., latanoprost, bimatoprost), not topical beta blockers. - This change in eye color occurs due to increased **melanin production** in melanocytes. *Asthma* - Topical beta blockers can be absorbed systemically and block **beta-2 receptors** in the lungs, leading to **bronchoconstriction** and exacerbating **asthma**. - This side effect is particularly concerning in patients with a history of **reactive airway disease**. *Hypoglycemia* - Topical beta blockers are listed as a concern for **hypoglycemia risk** because they **mask the adrenergic symptoms of hypoglycemia** (tremor, palpitations, tachycardia). - While they don't directly cause hypoglycemia, masking these warning symptoms can lead to **delayed recognition and treatment**, particularly dangerous in **diabetic patients on insulin or sulfonylureas**. *Bradycardia* - Systemic absorption of topical beta blockers can lead to a decrease in **heart rate** (bradycardia) by blocking **beta-1 receptors** in the heart. - This effect is a significant concern for patients with pre-existing **cardiac conduction disorders** or those taking other medications that lower heart rate.
Question 8: Mechanism of action of teduglutide in short bowel syndrome:-
- A. GLP-2 analogue (Correct Answer)
- B. C-peptide analogs
- C. 5-HT1A inhibitor
- D. GLP-1 analogs
Explanation: ***GLP-2 analogue*** - **Teduglutide** is a synthetic analogue of **glucagon-like peptide-2 (GLP-2)**, a naturally occurring hormone. - It works by binding to **GLP-2 receptors** in the gut, promoting intestinal adaptation and fluid absorption. *C-peptide analogs* - **C-peptide** is a byproduct of insulin production and its analogs are not used for treating short bowel syndrome. - Its primary role is often studied in relation to **diabetes** and metabolic function, not intestinal growth. *5-HT1A inhibitor* - **5-HT1A inhibitors** act on serotonin receptors in the brain, typically used in conditions like **anxiety** and depression. - They have no direct pharmacological effect on intestinal adaptation or nutrient absorption in short bowel syndrome. *GLP-1 analogs* - **GLP-1 (glucagon-like peptide-1) analogs** are primarily used in the management of **type 2 diabetes** to improve glycemic control by stimulating insulin release and reducing glucagon secretion. - While GLP-1 has some effects on gastric emptying, it does not directly promote the profound **intestinal growth** and adaptation beneficial in short bowel syndrome as GLP-2 does.
Question 9: Which of the following is an H2 receptor antagonist used as an anti-ulcer drug?
- A. Pirenzepine
- B. Famotidine (Correct Answer)
- C. Rabeprazole
- D. Sucralfate
Explanation: ***Famotidine*** - **Famotidine** is a potent and selective **H2 receptor antagonist** that works by blocking histamine H2 receptors on parietal cells, thereby reducing gastric acid secretion. - It is widely used for the treatment of **peptic ulcers**, gastroesophageal reflux disease (**GERD**), and other acid-related disorders. *Pirenzepine* - **Pirenzepine** is a **selective M1 muscarinic antagonist**, which inhibits gastric acid secretion by blocking cholinergic pathways. - While it was previously used as an anti-ulcer drug, its mechanism of action is distinct from H2 receptor antagonism. *Rabeprazole* - **Rabeprazole** is a **proton pump inhibitor (PPI)** that irreversibly blocks the H+/K+-ATPase pump in gastric parietal cells, leading to a profound and prolonged reduction in gastric acid production. - Its mechanism is different from H2 receptor antagonists. *Sucralfate* - **Sucralfate** is a **cytoprotective agent** that forms a viscous, protective gel that adheres to ulcerated areas, shielding them from acid, pepsin, and bile. - It does not directly inhibit acid secretion but rather provides a physical barrier and promotes healing.
Question 10: Which of the following statement is correct regarding the given DRC? (AllMS Nov 2016)
- A. C is non-competitive antagonist
- B. B is more potent than A
- C. A is more efficacious than B
- D. A and B are full agonists (Correct Answer)
Explanation: ***A and B are full agonists*** - Both Drug A and Drug B reach the **maximum biological effect**, indicated as 100 on the y-axis, meaning they are capable of producing the full response. - A full agonist is a substance that binds to a receptor and produces the **maximum possible biological response**. *C is non-competitive antagonist* - Drug C *does* produce a biological effect, albeit a lower one, making it a **partial agonist**, not an antagonist. - A non-competitive antagonist would **reduce the maximum effect** of the agonist and shift the curve downwards, which is not what is observed here for C. *B is more potent than A* - Drug A achieves 50% of its maximal effect at a **lower concentration** than Drug B (i.e., further to the left on the x-axis). - Therefore, Drug A is **more potent** than Drug B, as potency is inversely related to the concentration required for a given effect. *A is more efficacious than B* - Both Drug A and Drug B reach the **same maximum biological effect** (100 on the y-axis), indicating they have equal efficacy. - Efficacy refers to the **maximum effect** a drug can produce, regardless of the dose.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free